Elvitegravir: A once-daily, boosted, HIV-1 integrase inhibitor

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 1, 2012, Pages 13-20

  Lampiris, Harry W ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

cobicistat; elvitegravir; HIV 1 integrase; integrase drug interactions; integrase inhibitor; integrase pharmacokinetics; integrase resistance

Indexed keywords

ANTACID AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; COBICISTAT; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; KETOCONAZOLE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; OMEPRAZOLE; RALTEGRAVIR; RIFABUTIN; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; TENOFOVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR;

ABDOMINAL DISTENSION; ABNORMAL DREAMING; ABNORMAL LABORATORY RESULT; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BEDTIME DOSAGE; CENTRAL NERVOUS SYSTEM DISEASE; CREATININE BLOOD LEVEL; CROSS RESISTANCE; DIARRHEA; DOSE RESPONSE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GLOMERULUS FILTRATION; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERAMYLASEMIA; HYPERCHOLESTEROLEMIA; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; IC 50; IN VITRO STUDY; IN VIVO STUDY; KIDNEY DISEASE; MAXIMUM PLASMA CONCENTRATION; MUSCLE SPASM; NAUSEA; NIGHTMARE; NONHUMAN; OPTIMAL DRUG DOSE; RASH; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VIRUS MUTATION; VIRUS VIRULENCE;

CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; DRUG TOXICITY; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 83455233809     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.157     Document Type: Article

References (42)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338, 853-860 (1998).
2. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372, 293-299 (2008).
3. Hicks C, Gulick RM. Raltegravir: the first HIV type 1 integrase inhibitor. Clin. Infect. Dis. 48, 831-939 (2009).
4. Malet I, Delelis O, Valantin MA, et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob. Agents 52, 1351-1358 (2008).
5. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analysis of raltegravir for resistant HIV-1 infection. N. Engl. J. Med. 359, 355-365 (2008).
6. Metifiot M, Marchand C, Maddali K, et al. Resistance to integrase inhibitors. Viruses 2, 1347-1366 (2010).
7. Mouscadet JF, Delelis O, Marcelin AG, et al. Resistance to HIV-1 integrase inhibitors: a structural perspective. Drug Resist. Updat. 13, 139-150 (2010).
8. Blanco JL, Verghese V, Rhee SY, et al. HIV-1 integrase inhibitor resistance and its clinical implications. J. Infect. Dis. 203, 1204-1214 (2011).
9. Hare S, Gupta SS, Valkov E, et al. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 464, 232-237 (2011).
10. Shun MC, Raghavendra NK, Vandegraff N, et al. LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integrase. Genes Dev. 21, 1767-1778 (2007).
11. Marshall HM, Ronen K, Berry C, et al. Role of PSIP1/LEDGF/p75 in lentiviral infectivity and integration targeting. PLoS One 2, e1340 (2007).
12. Hazuda DL, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287, 646-650 (2000).
13. Sato M, Kawakami H, Motomura T, et al. Quinolone carboxylic acids as a novel monoketo acid class of human immunodeficiency virus type I integrase inhibitors. J. Med. Chem. 52, 4869-4882 (2009).
14. Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin. Pharmacol. Ther. 87, 322-329 (2010).
15. Roquebert B, Damond F, Collin G, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J. Antimicrob. Chemoth. 62, 914 (2008).
16. Shimura K, Kodama E, Sakagami Y, et al. Broad anti-retroviral activity and resistance profile of a novel human immunodeficiency virus integrase inhibitor, elvitegravir (JTK-303/GS-9137). J. Virol. 82, 764-774 (2008).
17. Sichtig N, Sierra S, Kaiser R, et al. Evolution of raltegravir resistance during therapy. J. Antimicrob. Chemother. 52, 1351-1358 (2009).
18. Canducci F, Sampaolo M, Marinozzi MC, et al. Dynamic pattern of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS 23, 455-460 (2009).
19. Hatano H, Lampiris H, Fransen H, et al. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 54, 389-393 (2010).
20. Metifiot M, Vandegraaff N, Maddali K, et al. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. AIDS 25, 1175-1178 (2011).
21. Fransen S, Gupta S, Danovich R, et al. Loss of raltegravir susceptibility of HIV-1 is conferred by multiple non-overlapping genetic pathways. J. Virol. 83, 11440-11446 (2009).
22. Mbisa JL, Martin SA, Cane PA. Patterns of resistance development with integrase inhibitors in HIV. Infect. Drug Resist. 4, 65-76 (2011).
23. Delelis O, Malet I, Na L, et al. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148 mutation. Nucleic Acids Res. 37, 1193-1201 (2009).
24. Seki T, Kobayashi M, Wakasa-Morimoto C, et al. S/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 16-19 February 2010 (Abstract 555).
25. DaSilva D, Van Wesenbeeck L, Beilh D, et al. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. J. Antimicrob. Chemother 65, 1262-1269 (2010).
26. McColl, DJ, Fransen S, Gupta S, et al. Resistance and cross-resistance to first generation integrase inhibitors: insights from a Phase II study of elvitegravir (GS-9137). Antivir. Ther. 12, S11 (2007).
27. McColl DJ, Chen X. Strand transfer inhibitors of HIV-1 integrase: bringing in a new era of antiretroviral therapy. Antivir. Res. 85, 101-118 (2010).
28. Kawaguchi I, Ishikawa T, Ishibashi M, et al. Safety and pharmacokinetics of single oral dose of JTK-303/GS-9137, a novel HIV integrase inhibitor, in healthy volunteers. Presented at: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA, 5-8 February 2006 (Abstract 580).
29. German P, Warren D, Wei L, et al. Effect of food on pharmacokinetics of elvitegravir, emtricitabine, tenofovir DF and the pharmacoenhancer GS-9350 as a fixed-dose combination tablet. Presented at: 49th International Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009 (Abstract A1-1300).
30. Ramanathan S, Khariton T, West S, et al. Population pharmacokinetics of ritonavir-boosted elvitegravir in adult healthy subjects and HIV-infected patients. Rev. Antivir. Ther. 3, 78 (2008).
31. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J. Acquir. Immune Defic. Syndr. 43, 1-5 (2006).
32. German P, Warren D, West S, et al. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J. Acquir. Immune Defic. Syndr. 55, 323-329 (2010).
33. Cohen C, Elion R, Ruane P, et al. Randomized, Phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 25, F7-F12 (2011).
34. Zolopa AR, Berger DS, Lampiris H, et al. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV type 1: results of a Phase 2, randomized, controlled, dose-ranging clinical trial. J. Infect. Dis. 201, 814-822 (2010).
35. Ramanathan S, Mathias AA, Hinkle J, et al. Clinical pharmacology of the HIV integrase inhibitor elvitegravir. Presented at: 11th European AIDS Conference. Madrid, Spain, 24-27 October 2007 (Abstract PS 4/7).
36. Molina, J-M, LaMarca A, Andrade-Villanueva J, et al. Elvitegravir once-daily is non-inferior to raltegravir twice-daily in treatment experienced patients: 48 week results from a Phase 3, multicenter, randomized, double blind study. Presented at: 6th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. Rome, Italy, 17-20 July 2011 (Abstract WELBB05).
37. Ramanathan S, Mathias AA, German P, et al. Clinical pharmacokinetic and pharmacodynamics profile of the HIV integrase inhibitor elvitegravir. Clin. Pharmacokinet. 50, 229-244 (2011).
38. Ramanathan S, Abel S, Tweedy S, et al. Pharmacokinetic interactions of ritonavir-boosted elvitegravir and maraviroc. J. Acquir. Immune Defic. Syndr. 53, 209-214 (2010).
39. Ramanathan S, Shen G, Hinkle J. Pharmacokinetic evaluation of drug interactions with ritonavir-boosted HIV integrase inhibitor GS-9137 (elvitegravir) and acid-reducing agents. Presented at: 8th International Workshop on Clinical Pharmacology of HIV Therapy. Budapest, Hungary, 16-18 April 2007 (Abstract 69).
40. Norvir® package insert, Abbott Laboratories, Chicago, IL, USA, revised April 2010.
41. Gileads investigational antiretroviral QUAD regimen meets 48 week primary objective in pivotal Phase 3 clinical study 102. Gilead Sciences Press Release, August 15 2011. www.gilead.com/pr-1596378
42. Gileads second pivotal Phase 3 clinical study of the investigational antiretroviral QUAD regimen meets 48-week primary objective. Gilead Sciences Press Release, September 19 2011. www.gilead.com/pr-1608125